

Open Targets: enabling systematic target discovery

Biogen


March 21st 2018


Denise Carvalho-Silva, PhD

Scientific Outreach Lead

Open Targets / EMBL-EBI

Wellcome Genome Campus, United Kingdom





Biogen Joins Pioneering Target Validation Collaboration

The Centre for Therapeutic Target Validation Welcomes New Member Biogen, Expanding Its Efforts to Accelerate Drug Discovery Research

- Feb 2016
- New name (from CTTV → Open Targets)
- Jeff Barrett (Open Targets Director): pastures new in 2018

In these ~ 2 hours



What is the Open Targets
Partnership?

How to navigate the
Open Targets Platform?



Are there other Open
Targets tools?

Where do I get help?

Our Vision

<https://www.opentargets.org>

A partnership to transform drug discovery
through the systematic identification and
prioritisation of targets



2014

2016

2017

What does Open Targets want?


- Systematically find the best targets for safe and effective medicines
- Help others find good targets
- Get these targets adopted into drug discovery pipelines



High throughput
human genetics



Organoids
IPS cells



Make target
decisions
together



Advanced
data analysis

What do users want?




**Open Targets Platform
is all you need!**

All relevant data in one place
one-stop shop
new analyses
original

comprehensive
trustworthy
up-to-date
sustainable
easy-to-use
resource

Virtuous cycle in Open Targets




Concurrent
www.opentargets.org/projects

Open Targets Platform

<https://www.targetvalidation.org>


- Associations between targets and diseases



- Target centric and disease centric information



Our targets → genes or proteins

- Ensembl Gene IDs e.g. ENSGXXXXXXXXXXXX
- UniProt IDs e.g. P15056
- HGNC names e.g. DMD
- Also non-coding RNA genes
- Metabolites: to come




Our diseases

- Experimental Factor Ontology (EFO)
- Controlled vocabulary (Alzheimers versus alzheimer's)
- Hierarchy (relationships)
 - Promotes consistency
 - Increases the richness of annotation
 - Allow for easier and automatic integration



Our evidence for T-D associations




www.targetvalidation.org/data_sources

Data sources grouped into seven data types

Genetic Associations	Somatic Mutations	Drugs	Affected Pathways	Differential RNA expression	Animal Models	Text Mining
 UniProt	 UniProt	 chEMBL	 reactome	 Expression Atlas	 PhenoDigm	 Europe PMC
 EVA	 EVA			 SLAPenrich		
 Genomics England	 COSMIC Catalogue Of Somatic Mutations In Cancer					
 GWAS Catalog	 intOgen					
 PheWAS						
 G2P						

More data sources to come

How the data* flows



JSON summary document

```

hort_name": "Franke A"}, {"last_name": "Alizadeh", "full_name": "Alizadeh Behrooz Z", "short_name": "Alizadeh BZ"}, {"last_rkes Miles", "short_name": "Parkes M"}, {"last_name": "B K", "full_name": "B K Thelma", "short_name": "B K T"}, {"last_name": "k J", "short_name": "Daly MJ"}, {"last_name": "Kubo", "full_name": "Kubo Michiaki", "short_name": "Kubo M"}, {"last_name": "n Carl A", "short_name": "Anderson CA"}, {"last_name": "Weersma", "full_name": "Weersma Rinse K", "short_name": "Weersma RK"}al_data": {"medlineAbbreviation": "Nat. Genet.", "title": "Nature genetics"}, "target": {"activity": "predicted_damaging", "name": "integrin subunit alpha L", "geneid": "ENSG00000005844"}, "id": "ENSG00000005844", "target_type": "gene_evidence"}, ceID": "gwas_catalog", "variant": {"type": "snp single", "id": "http://identifiers.org/dbsnp/rs11150589"}, "disease": {"efo_bels": ["immune system disease", "digestive system disease"], "codes": ["EFO_0000405", "EFO_0000540"]}, "path": [[["EFO_000040", "EFO_0005140", "EFO_0003767"]]}, "efo_id": "http://www.ebi.ac.uk/efo/EFO_0003767", "label": "inflammatory bowel disease" _association_fields": {"pubmed_refs": "http://europepmc.org/abstract/MED/26192919", "object": "http://www.ebi.ac.uk/efo/EFO_ntifiers.org/dbsnp/rs11150589", "study_name": "cttv009_gwas_catalog", "sample_size": "96486", "gwas_panel_resolution": "9000 : "http://identifiers.org/ensembl/ENSG00000005844"}, "evidence": {"variant2disease": {"gwas_sample_size": 96486, "unique_expepmc.org/abstract/MED/26192919", "gwas_panel_resolution": 9000000, "provenance_type": {"literature": {"references": [{"lit_act/MED/26192919"]}}}, "expert": {"status": true, "statement": "Primary submitter of data"}, "database": {"dbxref": {"version": "id": "http://identifiers.org/gwascatalog"}, "id": "GWAS Catalog", "version": "2017-03-23T03:44:36+00:00"}, "is_associated": "pvalue", "method": {"description": "pvalue for the snp to disease association."}, "value": 9e-07}, "evidence_codes": [{"http://purl.obolibrary.org/obo/ECO_0000205", "http://purl.obolibrary.org/obo/ECO_0000205", "http://identifiers.org/eco/ctt rted": "2017-03-23T03:44:36+00:00"}, "evidence_codes_info": [{"{"eco_id": "GWAS", "label": "Genome-wide association study ev: ing_pipeline", "label": "CTTV-custom annotation pipeline"}], [{"{"eco_id": "ECO_0000205", "label": "curator inference"}], [{"{"upstream_gene_variant"}]}, "gene2variant": {"functional_consequence": "http://purl.obolibrary.org/obo/SO_0001631", "provenan true, "statement": "Primary submitter of data"}, "database": {"dbxref": {"version": "2017-03-23T03:44:36+00:00", "id": "http://identifiers.org/gwascatalog"}, "id": "GWAS Catalog", "version": "2017-03-23T03:44:36+00:00"}, "is_associated": true, "resource_score": {"type": "probab codes": [{"http://purl.obolibrary.org/obo/ECO_0000205", "http://identifiers.org/eco/cttv_mapping_pipeline"}], "date_asserted": "2017-03-23T03:44:36+00:00"}, "evidence_codes": [{"GWAS", "cttv_mapping_pipeline", "ECO_0000205", "SO_0001631"}], "validated_against_schema_version": "1.2.9", "res": {"association_score": 0.24183029962242697}, "type": "genetic_association", "id": "f8aa5612c7f01940f3958914fc6074ba"}} loads denise$
```

* IDs (gene, disease, papers) + curation (e.g. manual) + evidence + source + stats for the score



Association score: 0 → 1



How confident can I be
in the Open Targets
T-D associations?

$$S_1 + S_2/2^2 + S_3/3^2 + S_4/4^2 + S_i/i^2$$

Statistical integration, aggregation and scoring

- A) per evidence (e.g. one SNP from a GWAS paper)
- B) per data source (e.g. SNPs from the GWAS catalog)
- C) per data type (e.g. Genetic associations score)
- D) overall association score


Four-tier framework

Score: 0 to 1 (max)

Calculated at 4 levels:

- Evidence
- Data source
- Data type
- Overall

Aggregation with
(harmonic sum) Σ_H



Note: Each data set has its own scoring and ranking scheme

$$\Sigma_H = S_1 + S_2/2^2 + S_3/3^2 + S_4/4^2 + \dots + S_i/i^2$$

Factors affecting the relative strength of an evidence


e.g. **GWAS Catalog**

$$S = f * s * c$$

f, relative occurrence of a target-disease evidence

s, strength of the effect described by the evidence

c, confidence of the observation for the target-disease evidence





f = sample size (cases versus controls)

s = predicted functional consequence (VEP)

c = *p* value reported in the paper

Ranking the target-disease association



Association score: the overall score across all data types

- Based on the data sources
- Different weight applied:

genetic association = drugs = mutations = pathways > RNA expression > animal models = text mining

In addition to T-D associations

- Everything you wanted to know about...



... but were afraid to ask.

The screenshot shows the Open Targets Platform interface. At the top, there's a blue header bar with the "Open Targets Platform" logo and a search icon. Below the header, the main content area has a title "Evidence for CD86 in multiple sclerosis". On the left, there's a circular diagram with several overlapping ovals representing different data sources: "Text Mining", "RNA", "Pathways", "Drugs", "Mouse", "Somatic", and "Genetics". To the right of this diagram, there's a box for the "CD86" molecule, which includes its name, definition ("CD86 molecule"), and synonyms ("Synonyms: B7.2, B7-2, CD28LG2"). A blue callout bubble points to this box with the text "Target profile page". Further down, another box is labeled "multiple sclerosis", listing its synonyms ("Synonyms: MS (Multiple Sclerosis), MS, MULTIPLE SCLEROSIS ACUTE FULMINATING, Disseminated Sclerosis, Sclerosis...") and a blue callout bubble points to it with the text "Disease profile page".

Evidence for CD86 in multiple sclerosis

CD86

CD86 molecule

Synonyms: B7.2, B7-2, CD28LG2


multiple sclerosis

Synonyms: MS (Multiple Sclerosis), MS, MULTIPLE SCLEROSIS ACUTE FULMINATING, Disseminated Sclerosis, Sclerosis...

Target profile page

Disease profile page

Profile of a drug target




Protein	Drugs	Pathways interactions	RNA and protein baseline expression	Variants, isoforms and genomic context	Mouse phenotypes	Bibliography
		Protein Interactions 	 Expression Atlas			
 Protein Data Bank in Europe				Gene tree		Library/LINK
Description Synonyms Gene Ontology Protein Structure		Similar Targets 				

Extra, extra, extra!

Cancer hallmarks in our latest release!

<http://www.targetvalidation.org/target/ENSG00000141510>


Profile of a disease

Classification	Drugs	Similar diseases	Bibliography
 		 	 Open Targets Library/LINK 

http://www.targetvalidation.org/disease/Orphanet_262

I of targeting the
Journal of cellular physiology 2018 233(3):2162-2169
Majid Khazaei, Seyyed

How to access all of this



* UI: first released in December 2015

<https://www.targetvalidation.org>

** API first release in April 2016

<https://api.opentargets.io>

Demo 1: Disease centric workflow

Which targets are associated with a disease?



What is the evidence for the association between a target and a disease?

Find new targets for drug discovery

multiple sclero 🔍

multiple sclerosis
2697 targets associated

💡 Disease

An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include vis...

Targets

MBP myelin basic protein

Diseases

relapsing-remitting **multiple sclerosis**
autoimmune disease > multiple sclerosis > relapsing-remitting multiple ...

<https://www.targetvalidation.org/>

Choose your favourite internet browser*

*Supported ones: Internet Explorer 11 (not earlier versions), Chrome, Firefox, Safari

Demo 2: Several targets at once



We have a list of 26 possible targets for IBD.

Are these targets represented in other diseases?

Which pathways are represented in this set of targets?

Coursebook

bit.ly/biogen210318

pages 29-32


Text file for exercise 4

bit.ly/biogen18


Other Open Targets resources

<http://link.opentargets.io/>

- LINK: Literature coNcept Knowledgebase
- Subject / predicate / object structured relations



Addressing text mining shortcomings



- Entities: genes, diseases, drugs
- Concepts extracted via NLP
(Natural Language Processing)
- 28 M documents, 500 M relations
- <http://blog.opentargets.org/link/>

LRRK1 Irrk1 play in Parkinson's disease pd

In contrast, LRRK1 GENE, the closest homologue to LRRK2, does not play any role in PD DISEASE CONCEPT.

PubMed: 28819229 2017-08-17

DoRothEA

dorothea.opentargets.io



DoRothEA Discriminant Regulon Expression Analysis

Home

TF-Drug Interactions

TF-Pharmacogenomic Marker Interactions

- Candidate TF-drug interactions in cancer
- 1000 cancer cell lines
- 265 anti-cancer compounds
- 127 transcription factors

TP53, Nutlin-3a, MDM2

Home TF-Drug Interactions TF-Pharmacogenomic Marker Interactions


- Filter by drug
 Filter by transcription factor

Transcription factor

Select a transcription factor ▾

Selected interaction

Drug	Nutlin-3a
Transcription Factor	TP53
Effect Size	-0.572
FDR	5.34e-26
P Value	1.59e-30
Drug Targets	MDM2



Open Targets Platform

- Resource of integrated genetics, genomics and drug info
- Added value (e.g. scores)
- Graphical web interface

Not yet a bespoke
resource that works for you?
User design research.

2 targets

cases

2.3 M
associations

5.9 M
evidence

February 2018 release

Putting our users first



- Andrew Hercules
User experience designer

The image consists of two main parts. On the left is a wireframe for a 'GENE / PROTEIN T1' entry page. The page includes sections for 'DATA SOURCE 1' (with a 'Gene' section), 'DATA SOURCE 2' (with a 'Protein' section), and 'DATA SOURCE 3' (with a 'Summary of key relationships of this gene to original study'). A sidebar on the right shows 'Three sources of data' (Text, Figures, Literature) and a 'raw data' section with a table for 'COPD smokers' and 'COPD ex-smoker'. Handwritten annotations provide user feedback such as 'Epigenetic data > expression data (communicator network)', 'not clear what these are (unexplained)', 'type of line describes connection (this one is solid, so there's a connection)', 'Network Associations CONFUSED', 'abstract ... gene entry', 'more info (expand)', 'both search parameters "active" at once', 'Doesn't make sense for this to be a network of other genes ...', 'CONFUSED (but hard to leave early)', 'anything that was in the file', 'Filters should be represented here.', 'is it really useful to have microarray data when you've already zoomed in on a disease?', 'would try to download data and analyse it myself', and 'TP2'.


Your feedback is important

<https://bit.ly/biogen-feedback>

Help shape the navigation bar

<http://bit.ly/ot-nav-cs>

Virtuous cycle in Open Targets



Concurrent
www.opentargets.org/projects

We support decision-making

Which targets are associated with a disease?


Can I find out about the mechanisms of the disease?

Are there FDA drugs for this association?



...

Other modes of Platform data access



REST API calls: some examples*

GET

/public/search

https://api.opentargets.io/v3/platform/public/search?q=EFO_0003767

<https://api.opentargets.io/v3/platform/public/search?q=asthma>

GET

/public/association/filter

[https://api.opentargets.io/v3/platform/public/association/filter?
target=ENSG00000110324&direct=false&fields=is_direct&fields=disease.efo_info.lab
el&size=100](https://api.opentargets.io/v3/platform/public/association/filter?target=ENSG00000110324&direct=false&fields=is_direct&fields=disease.efo_info.label&size=100)

GET

/public/evidence/filter

[https://api.opentargets.io/v3/platform/public/evidence/filter?
target=ENSG00000141867&disease=EFO_0000565&datatype=expression_atl
as&size=100&format=json](https://api.opentargets.io/v3/platform/public/evidence/filter?target=ENSG00000141867&disease=EFO_0000565&datatype=expression_atlas&size=100&format=json)

Several ways to run our REST endpoints

- Paste the URL in the location bar in a browser
- Use the terminal window (e.g. with CURL command)
- Use our free clients (i.e. Python* and R)
- Call them from your own application/workflow

* <http://opentargets.readthedocs.io/en/stable/index.html>

REST API

<http://api.opentargets.io/v3/platform/docs#>

API ▾ Downloads Blog

API documentation

Python client



Open Targets

Search

PUBLIC >

PRIVATE >

AUTH >

UTILS >

Open Targets Platform REST API (v3)

Download OpenAPI specification: [Download](#)

Contact: support@targetvalidation.org License: Apache 2.0

The Open Targets Platform REST API

The Open Targets Platform API ('Application Programming Interface') allows you to interact with our platform via a series of REST services.

You can make calls to the latest version of our API using the base URL

<https://api.opentargets.io/v3/platform>. Please make sure you

use <https://api.opentargets.io/v3/platform> calls, which we do not accept. Note that we only serve the latest version of our API. If you are querying an old version, please [get in touch](#) so that we can help.

We list below the methods available for you to query our data directly from the browser. These are generated from our Swagger UI. For every request you create, the interface will generate a curl command that you can copy and paste directly to a shell to obtain the same results without using an intermediate step.

Check our [API blog posts](#), for tutorials and additional information on how to a

Search

PRIVATE

GET getApiDocs

GET getAutocomplete

POST postBestHitSearch

POST postDiseaseById

GET getDiseaseById

GET getECObyID

POST postEnrichmentTarget

GET getQuickSearch

POST postRelation

<http://api.opentargets.io/v3/platform/docs#>

Private: methods used by the UI to serve external data.
Subject to change without notice

Where to find out more

Published online 8 December 2016

Nucleic Acids Research, 2017, Vol. 45, Database issue D985–D994
doi: 10.1093/nar/gkw1055



Open Targets: a platform for therapeutic target identification and validation

Gautier Koscielny^{1,2,*}, Peter An^{1,3}, Denise Carvalho-Silva^{1,4}, Jennifer A. Cham^{1,4}, Luca Fumis^{1,4}, Rippa Gasparyan^{1,3}, Samiul Hasan^{1,2}, Nikiforos Karamanis^{1,4}, Michael Maguire^{1,4}, Eliseo Papa^{1,3}, Andrea Pierleoni^{1,4}, Miguel Pignatelli^{1,4}, Theo Platt^{1,3}, Francis Rowland^{1,4}, Priyanka Wankar^{1,3}, A. Patrícia Bento^{1,4}, Tony Burdett^{1,4}, Antonio Fabregat^{1,4}, Simon Forbes^{1,5}, Anna Gaulton^{1,4}, Cristina Yenyxe Gonzalez^{1,4}, Henning Hermjakob^{1,4,6}, Anne Hersey^{1,4}, Steven Jupe^{1,4}, Şenay Kafkas^{1,4}, Maria Keays^{1,4}, Catherine Leroy^{1,4}, Francisco-Javier Lopez^{1,4}, Maria Paula Magarinos^{1,4}, James Malone^{1,4}, Johanna McEntyre^{1,4}, Alfonso Munoz-Pomer Fuentes^{1,4}, Claire O'Donovan^{1,4}, Irene Papatheodorou^{1,4}, Helen Parkinson^{1,4}, Barbara Palka^{1,4}, Justin Paschall^{1,4}, Robert Petryszak^{1,4}, Naruemon Pratanwanich^{1,4}, Sirarat Sarntivijal^{1,4}, Gary Saunders^{1,4}, Konstantinos Sidiropoulos^{1,4}, Thomas Smith^{1,4}, Zbyslaw Sondka^{1,5}, Oliver Stegle^{1,4}, Y. Amy Tang^{1,4}, Edward Turner^{1,4}, Brendan Vaughan^{1,4}, Olga Vrousou^{1,4}, Xavier Watkins^{1,4}, Maria-Jesus Martin^{1,4}, Philippe Sanseau^{1,2}, Jessica Vamathevan⁴, Ewan Birney^{1,4}, Jeffrey Barrett^{1,4,5} and Ian Dunham^{1,4,*}

¹Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK, ²GSK, Medicines Research Center, Gunnels Wood Road, Stevenage, SG1 2NY, UK, ³Biogen, Cambridge, MA 02142, USA, ⁴European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK, ⁵Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK and ⁶National Center for Protein Research, No. 38, Life Science Park Road, Changping District, 102206 Beijing, China

Received August 19, 2016; Revised October 19, 2016; Editorial Decision October 20, 2016; Accepted November 03, 2016

Acknowledgements



Help!



support@targetvalidation.org



<https://tinyurl.com/opentargets-youtube>



[@targetvalidate](#)



<http://tinyurl.com/opentargets-in>







blog.opentargets.org/

Specs on data sources for the Open Targets Platform

Data sources: GWAS catalog


- Genome Wide Association Studies
- Array-based chips → genotyping 100,000 SNPs genomewide



Open Targets

Data sources: UniProt

- Protein: sequence, annotation, function



- Manual curation of coding variants in patients




EMBL-EBI train online



Open Targets

Data sources: Gene2Phenotype



Gene2Phenotype Downloads


Search panel ALL for: **Search**

For example: **CRYBA1, ZEB2, TBX1, CHANARIN-DORFMAN SYNDROME or MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1**

- Variants, genes, phenotypes in rare diseases
- Literature curation → consultant clinical geneticists in the UK

Data sources: UniProt

- Protein: sequence, annotation, function



- Manual curation of coding variants in patients




EMBL-EBI train online



Open Targets


Data sources: PheWAS

- Phenome Wide Association Studies
- A variant associated with multiple phenotypes
- Clinical phenotypes derived from EMR-linked biobank BioVU
- ICD9 codes mapped to EFO



Data sources: GE PanelApp

- Aid clinical interpretation of genomes for the 100K project
- We include ‘green genes’ from version 1+ and phenotypes



Germline
variants

Somatic
mutations

Data sources: EVA

- With ClinVar information for rare diseases
- Clinical significance: pathogenic, protective

The screenshot shows the European Variation Archive (EVA) Clinical Browser interface. The top navigation bar includes links for Home, Submit Data, Study Browser, Variant Browser, Clinical Browser (which is highlighted in dark blue), GA4GH, API, FAQ, and Feedback. Below the navigation is a search bar with a magnifying glass icon and a "Filter" button. To the right of the search bar is the title "ClinVar Browser" with an information icon. The main content area displays a table of ClinVar variants. The table has columns for Position, Affecte..., Most Severe Consequence..., Trait, Clinical Significance, and ClinVar ID. The first few rows show variants for the MSH6 gene on chromosome 2, with positions ranging from 480,000,000 to 490,000,000. The clinical significance for most variants is listed as Benign.

...	Posi...	Affecte... i	A...	Most Severe Consequence...	Trait	Clinical Significance	ClinVar ...
2	480...	MSH6	T/G	upstream_gen...	Lynch synd...	Benign	RCV000...
2	480...	MSH6	G/A	upstream_gen...	Lynch synd...	Benign	RCV000...
2	480...	MSH6	C/T	upstream_gen...	Lynch synd...	Benign	RCV000...
2	480...	MSH6	C/T	upstream_gen...	Lynch synd...	Benign	RCV000...
2	480...	MSH6	G/T	5_prime_UTR...	Lynch synd...	Uncertain s...	RCV000...
2	480...	MSH6	G/T	5_prime_UTR...	Hereditary ...	conflicting ...	RCV000...



Data sources: The Cancer Gene Census

Census

Breakdown

Abbreviations

The cancer Gene Census is an ongoing effort to catalogue those genes for which mutations have been causally implicated in cancer. The original census and analysis was published in [Nature Reviews Cancer](#) and supplemental analysis information related to the paper is also available.

- Genes with mutations causally implicated in cancer
- Gene associated with a cancer plus other cancers associated with that gene

Data sources: IntOGen

The screenshot shows the homepage of the intOGen website. At the top is a navigation bar with an orange gradient background. From left to right, it contains: the intOGen logo (a stylized orange 'i' icon followed by the word 'intOGen'), a 'Search' button with a magnifying glass icon, a 'Downloads' button with a download icon, an 'Analysis' button with a gear icon, an 'About' button with a speech bubble icon, and a 'Sign In' button with a user profile icon.

The main content area features the intOGen logo again, this time with the full name 'intOGen' in a large serif font next to a smaller orange 'i' icon. To the right of the name is the tagline 'Integrative Onco Genomics' in orange text.

- Genes and somatic (driver) mutations, 28 cancer types
- Involvement in cancer biology
- Rubio-Perez et al. 2015

Data sources: ChEMBL

EMBL-EBI

ChEMBL

EBI > Databases > Small Molecules > ChEMBL Database > Home

Search ChEMBL...

Compounds Targets Assays

Ligand Search Target Search Browse Targets Browse Drugs Browse Drug Targets

- Known drugs linked to a disease and a known target
- FDA approved for clinical trials or marketing



EMBL-EBI train online



Open Targets

Affected
pathways

Data sources: Reactome



The image shows the Reactome homepage. At the top left, there is a purple box containing the text "Affected pathways". The main title "REACTOME" is displayed in large white letters, with "A CURATED PATHWAY DATABASE" in smaller text below it. To the right of the title is a decorative graphic featuring a red sphere, blue and green abstract shapes, and arrows. Below the title is a navigation bar with links: "About", "Content", "Documentation", "Tools", "Community", "Download", and "Contact". To the right of the navigation bar is a search bar containing the placeholder text "e.g. O95631, NTN1, signalin" and a "Search" button.

- Biochemical reactions and pathways
- Manual curation of pathways affected by mutations




EMBL-EBI train online



Open Targets

Data sources: Expression Atlas



The screenshot shows the Expression Atlas website. At the top, there is a navigation bar with the EMBL-EBI logo, followed by links for Services, Research, Training, and About us. Below the navigation bar is a search bar with the placeholder "Enter gene query..." and a "Search" button. To the left of the search bar is a magnifying glass icon. The main title "Expression Atlas" is displayed prominently. Below the title is a horizontal menu bar with links for Home, Release notes, FAQ, Download, Help, Licence, and About. On the far right of this menu bar is a "Feedback" link.

- Baseline expression for human genes
- Differential mRNA expression (*healthy versus diseased*)



EMBL-EBI train online



Open Targets

Data sources: Europe PMC



Europe PMC

About

Tools

Developers

Help

Europe PMC plus

Search worldwide, life-sciences literature

- Mining titles, abstracts, full text in research articles
- Target and disease co-occurrence in the same sentence



EMBL-EBI train online



Open Targets

Data sources: PhenoDigm

The screenshot shows the homepage of the PhenoDigm website. At the top, there is a dark header bar with the Wellcome Trust Sanger Institute logo on the left. To the right of the logo is a blue navigation bar with the following links: "ABOUT" (with a dropdown arrow), "Who we are", "Careers", "Study", "Sex in Science", "Groups", and "Campus". On the far right of the blue bar is a magnifying glass icon representing a search function. Below the header, the main title "Welcome to PhenoDigm (PHENOtype comparisons for DIsease and Gene Models)" is displayed in large, bold, black font. Underneath the title, there is a horizontal menu bar with three items: "Diseases" (which is highlighted in blue), "Tissue phenotype associations", and "Secondary phenotypes".

Welcome to PhenoDigm (PHENOtype comparisons for DIsease and Gene Models)

Diseases Tissue phenotype associations Secondary phenotypes

- Semantic approach to associate mouse models with diseases

Aggregating scores across the data

- Using a mathematical function, the harmonic sum*


$$S_{1..i} = S_1 + \frac{S_2}{2^2} + \frac{S_3}{3^2} + \frac{S_4}{4^2} \dots + \frac{S_i}{i^2}$$

where S_1, S_2, \dots, S_i are the individual sorted evidence scores in descending order


- Advantages:
 - A) account for replication
 - B) deflate the effect of large amounts of data e.g. text mining

Target-Disease Association Score

EuropePMC
(Text Mining)




UniProt
(Manual Curation)



Overall

ChEMBL
(Manual Curation)



VERY simplified diagram

<https://www.targetvalidation.org/scoring>

Several ways to run our REST endpoints

- Paste the URL in the location bar in a browser
- Use the terminal window (e.g. with CURL command)
- Use our free clients (i.e. Python* and R)
- Call them from your own application/workflow

* <http://opentargets.readthedocs.io/en/stable/index.html>

Python and R clients for the REST API

opentargets
latest

Search docs

Tutorial
High Level API
Low Level API
Code Documentation
Changelog


Docs » opentargets - Python client for targetvalidation.org

Edit on GitHub

opentargets - Python client for targetvalidation.org

opentargets is the official python client for the [Open Targets REST API](#) at [targetvalidation.org](#)

<http://opentargets.readthedocs.io>



[https://blog.opentargets.org/
rest-api-exploration-using-
an-r-client/](https://blog.opentargets.org/rest-api-exploration-using-an-r-client/)

How to access Open Targets
with R